Home › Compare › GEAHF vs ABBV
GEAHF yields 7.00% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, GEAHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GEAHF + ABBV for your $10,000?
Great Eagle Holdings Limited, an investment holding company, invests in, develops, and manages residential, office, retail, and hotel properties in Asia, North America, Australasia, and Europe. The company operates through Hotel Operation, Property Investment, Property Development, Other Operations, Champion REIT, Langham, and US Real Estate Fund segments. The company engages in leasing furnished apartments and properties; and flexible workspace, asset management, hotel accommodation, food and banquet, and restaurant operations. It also owns and operates three hotels under The Langham, Cordis, and Eaton brand names. In addition, the company offers property management services, including security services, staff services, maintenance and repairs, consultancy services, as well as property maintenance, leasing, and agency services. Further, it trades in building materials; invests in securities; manages real estate investment trust, computer system solutions, project advisory, treasury management, investment, and investment fund management services, as well as real estate agency services; procurement and financing, and general trading services; and issues medium term notes. The company was founded in 1963 and is headquartered in Wanchai, Hong Kong.
Full GEAHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.